Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age

Wheeler, Cosette M.; Harvey, Bryan M.; Pichichero, Michael E.; Simon, Michael W.; Combs, Stephen P.; Blatter, Mark M.; Marshall, Gary S.; Catteau, Grégory; Dobbelaere, Kurt; Descamps, Dominique; Dubin, Gary; Schuind, Anne

doi:10.1097/inf.0b013e31822d28df

Cited by 30 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, co-administration of current HPV vaccines with other childhood combination vaccines against multiple infectious agents should also be considered since this potentially reduces the costs of vaccine administration. Indeed, some HPV co-immunization studies thus far have shown that antibody responses from either vaccine to be non-inferior to when administered alone (30-33). …”

Section: Improving Access To Current Vaccinesmentioning

confidence: 99%

Immunoprevention of Human Papillomavirus–Associated Malignancies

Wang

Hung

Huh

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

Persistent infection by one of fifteen high risk human papillomavirus (hrHPV) types is a necessary but not sufficient cause of 5% of all human cancers. This provides a remarkable opportunity for cancer prevention via immunization. Since Harald zur Hausen’s pioneering identification of hrHPV types 16 and 18, found in ~50% and ~20% of cervical cancers respectively, two prophylactic HPV vaccines containing virus-like particles (VLP) of each genotype have been widely licensed. These vaccines are beginning to impact infection and HPV-associated neoplasia rates after immunization campaigns in adolescents. Here we review recent progress and opportunities to better prevent HPV-associated cancers, including: broadening immune-protection to cover all hrHPV types, reducing the cost of HPV vaccines especially for developing countries that have the highest rates of cervical cancer, and immune-based treatment of established HPV infections. Screening based upon George Papanicolaou’s cervical cytology testing, and more recently detection of hrHPV DNA/RNA, followed by ablative treatment of high grade cervical intraepithelial neoplasia (CIN2/3) have substantially reduced cervical cancer rates, and we examine their interplay with immune-based modalities for the prevention and eventual elimination of cervical cancer and other HPV-related malignancies.

show abstract

Section: Improving Access To Current Vaccinesmentioning

confidence: 99%

Immunoprevention of Human Papillomavirus–Associated Malignancies

Wang

Hung

Huh

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…This study builds on results from other studies in adolescent girls, which have shown that the HPV-16/18 vaccine can be coadministered with other vaccines, such as DTaP-IPV, hepatitis B, Tdap, and meningococcal conjugate vaccines, without inter- fering with the immune response to either vaccine [25,36,37]. Coadministering vaccines at the same visit, rather than delivering vaccines at separate visits, will be of benefit in vaccination programs.…”

Section: Discussionmentioning

confidence: 79%

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

Pedersen

Breindahl

Aggarwal³

et al. 2012

Journal of Adolescent Health

Self Cite

View full text Add to dashboard Cite

“…Since licensure, four clinical trials have evaluated immunogenicity and safety of HPV-16/18-vaccine when co-administered with other vaccines likely to be used in adolescents and adults [26][27][28][29]. Study results indicate that HPV-16/18-vaccine can be co-administered safely with meningococcal serogroups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine (Menactra TM , Sanofi-Pasteur), combined diphtheria-tetanus-acellular pertussis vaccine (with or without inactivated poliomyelitis) (Boostrix TM , Boostrix TM Polio, GlaxoSmithKline Biologicals, Belgium), hepatitis B vaccine (HBV, Engerix TM B, GlaxoSmithKline Biologicals, Belgium) or combined hepatitis A and HBV vaccine (Twinrix TM , GlaxoSmithKline Biologicals, Belgium) [26][27][28][29].…”

Section: Co-administrationmentioning

confidence: 99%

Strategies for continuous evaluation of the benefit–risk profile of HPV-16/18-AS04-adjuvanted vaccine

Angelo¹,

Taylor²,

Struyf

et al. 2014

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

The HPV types 16/18-AS04-adjuvanted cervical cancer vaccine, Cervarix(®) (HPV-16/18-vaccine, GlaxoSmithKline, Belgium) was first approved in 2007 and is licensed in 134 countries for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by oncogenic HPV. Benefit-risk status requires continual re-evaluation as vaccine uptake increases, as the epidemiology of the disease evolves and as new information becomes available. This paper provides an example of benefit-risk considerations and risk-management planning. Evaluation of the benefit-risk of HPV-16/18-vaccine post-licensure includes studies with a range of designs in many countries and in collaboration with national public agencies and regulatory authorities. The strategy to assess benefit versus risk will continue to evolve and adapt to the changing HPV-16/18-vaccine market.

show abstract

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age

Abstract: Concomitant administration of HPV-16/18 AS04-adjuvanted vaccine with Tdap and/or MCV4 in different regimens did not interfere with the immune response to any of the vaccines and had an acceptable safety profile.

Cited by 30 publications

References 29 publications

Immunoprevention of Human Papillomavirus–Associated Malignancies

Immunoprevention of Human Papillomavirus–Associated Malignancies

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

Strategies for continuous evaluation of the benefit–risk profile of HPV-16/18-AS04-adjuvanted vaccine

Contact Info

Product

Resources

About